Vastness
Bluelight Crew
- Joined
- Mar 10, 2006
- Messages
- 2,318
Posting in this section as I figured it's the best chance of getting some informed insight into this question I've been wondering about.
Could anyone shed some light on the differences between the pharmaceutical research & approval process in Russia, compared to the Western world - specifically as it relates to the reasons why substances which are undoubtedly effective at doing something, are just seriously under-researched outside of Russia. For example, those mentioned in the thread title - phenibut, and phenylpiracetam.
One might argue they are of dubious real benefit for any real condition, but surely the same could be said for any number of members of the absurdly sized family of benzodiazepines, for example, in the case of phenibut... and at the moment it seems it's just not known either way, as a lot of these compounds have been essentially ignored by Western researchers. Why is this? If I were to guess I would assume it is simply down to economic machinations, that companies stand to profit more from substances they invent, research and manufacture themselves... is this the sadly blunt reality, or are there any other factors at play?
I wonder also what the approval process is like in Russia - the various tidbits of information I've read previously indicate that it is perhaps less strenuous than the FDA approval process, for example. The relative lack of a lot of research into the above mentioned substances, as well as other less well known ones, compared to vaguely equivalent medicines out of "big pharma" elsewhere, would seem to support this too...
Could anyone shed some light on the differences between the pharmaceutical research & approval process in Russia, compared to the Western world - specifically as it relates to the reasons why substances which are undoubtedly effective at doing something, are just seriously under-researched outside of Russia. For example, those mentioned in the thread title - phenibut, and phenylpiracetam.
One might argue they are of dubious real benefit for any real condition, but surely the same could be said for any number of members of the absurdly sized family of benzodiazepines, for example, in the case of phenibut... and at the moment it seems it's just not known either way, as a lot of these compounds have been essentially ignored by Western researchers. Why is this? If I were to guess I would assume it is simply down to economic machinations, that companies stand to profit more from substances they invent, research and manufacture themselves... is this the sadly blunt reality, or are there any other factors at play?
I wonder also what the approval process is like in Russia - the various tidbits of information I've read previously indicate that it is perhaps less strenuous than the FDA approval process, for example. The relative lack of a lot of research into the above mentioned substances, as well as other less well known ones, compared to vaguely equivalent medicines out of "big pharma" elsewhere, would seem to support this too...